bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
274 hedge funds and large institutions have $5.27B invested in bluebird bio in 2019 Q4 according to their latest regulatory filings, with 69 funds opening new positions, 92 increasing their positions, 70 reducing their positions, and 34 closing their positions.
103% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 34
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
44% more call options, than puts
Call options by funds: $103M | Put options by funds: $71.3M
31% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 70
14% more funds holding
Funds holding: 241 → 274 (+33)
0.54% less ownership
Funds ownership: 8.93% → 8.39% (-0.54%)
10% less capital invested
Capital invested by funds: $5.87B → $5.27B (-$597M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
+$83.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$48.3M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
+$46.2M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$40.1M |
| 5 |
Goldman Sachs
New York
|
+$30.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$331M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$232M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$142M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$75.9M |
| 5 |
CII
Capital International Inc
Los Angeles,
California
|
-$29.9M |
BLUE Hedge Fund Activity: Q4 2019 in Review
274 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q4 2019, worth a combined $5.27B — down 10% from $5.87B a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new BLUE positions and 34 closed out — a net gain of 35 holders — while 92 added to existing stakes and 70 trimmed.
The largest buyer was Sands Capital Management, adding an estimated $83.6M. The largest seller was Capital International Investors, cutting an estimated $331M.
- 274 institutional investors held bluebird bio (BLUE) as of Q4 2019, up from 241 in Q3 2019.
- Funds reported $5.27B of bluebird bio stock for Q4 2019, down 10% quarter-over-quarter.
- 69 funds opened new bluebird bio positions in Q4 2019 and 34 closed out, a net change of +35 holders.
- The largest bluebird bio buyer in Q4 2019 was Sands Capital Management, an estimated $83.6M added.
- The largest bluebird bio seller in Q4 2019 was Capital International Investors, an estimated $331M sold.
Based on aggregated 13F filings for Q4 2019.